Resistance to BRAF inhibitors in a patient with  BRAF  V600E-positive Langerhans cell histiocytosis

E. I. Lyudovskikh; Людовских Э. И.; D. A. Evseev; Евсеев Д. А.; D. S. Osipova; Осипова Д. С.; E. V. Raykina; Райкина Е. В.; I. I. Kalinina; Калинина И. И.; D. D. Baidildina; Байдильдина Д. Д.; A. A. Maschan; Масчан А. А.; M. A. Maschan; Масчан М. А.

doi:10.24287/1726-1708-2023-22-1-122-125

Resistance to BRAF inhibitors in a patient with BRAF V600E-positive Langerhans cell histiocytosis

Authors: Lyudovskikh E.I.¹, Evseev D.A.¹, Osipova D.S.¹, Raykina E.V.¹, Kalinina I.I.¹, Baidildina D.D.¹, Maschan A.A.¹, Maschan M.A.¹
Affiliations:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Issue: Vol 22, No 1 (2023)
Pages: 122-125
Section: CLINICAL OBSERVATIONS
Submitted: 21.11.2022
Accepted: 05.12.2022
Published: 14.02.2023
URL: https://hemoncim.com/jour/article/view/668
DOI: https://doi.org/10.24287/1726-1708-2023-22-1-122-125
ID: 668

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Here we report a clinical case of a patient with BRAF-positive Langerhans cell histiocytosis treated with combination therapy including trametinib. As the patient was undergoing long-term therapy with a BRAF inhibitor, his underlying disease reactivated. Hence it was suggested that the child might have become resistant to the treatment as a result of a subclonal mutation. It was concluded that this event undermined the efficacy of long-term therapy with BRAF inhibitors and highlighted the need for further study of possible molecular genetic mechanisms involved in the pathogenesis of Langerhans cell histiocytosis, as well as the need for the development of new treatment approaches. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.